Activation of the liver X receptor by agonist TO901317 improves hepatic insulin resistance via suppressing reactive oxygen species and JNK pathway

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Dong, Ying ^a,b   Gao, Guirong ^a   Fan, Hongyan ^a   Li, Shengxian ^a   Li, Xuhang ^b   Liu, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATASE; INSULIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PALMITIC ACID; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; FLUORINATED HYDROCARBON; ORPHAN NUCLEAR RECEPTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PROTEIN KINASE B; SULFONAMIDE; TO-901317;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DB/DB MOUSE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIVER METABOLISM; LIVER PARENCHYMA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; TREATMENT DURATION; WILD TYPE MOUSE; AGONISTS; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIPID METABOLISM; LIVER; METABOLISM; PHENOTYPE; PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS; RODENTIA;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCOSE; HEP G2 CELLS; HUMANS; HYDROCARBONS, FLUORINATED; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER X RECEPTORS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; ORPHAN NUCLEAR RECEPTORS; PHENOTYPE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 84929340733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124778     Document Type: Article

References (55)

1. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012; 59(7): 635-643. doi: 10.1016/j.jacc.2011.08.080 PMID: 22322078
2. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7(2): 95-96. doi: 10.1016/j.cmet.2007.12.009 PMID: 18249166
3. Steffensen KR, Jakobsson T, Gustafsson JÅ. Targeting liver X receptors in inflammation. Expert Opin Ther Targets. 2013; 17(8): 977-990. doi: 10.1517/14728222.2013.806490 PMID: 23738533
4. Venteclef N, Ferré P. Liver X receptor: from metabolism to cancer. Biochem J. 2014; 459(2): e1-3. doi: 10.1042/BJ20140211 PMID: 24678940
5. Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol. 2008; 59 Suppl 7: S31-55.
6. Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw. 2007; 3;61: 736-759. PMID: 18063918
7. Steffensen KR, Nilsson M, Schuster GU, Stulnig TM, Dahlman-Wright K, Gustafsson JÅ. Gene expression profiling in adipose tissue indicates different transcriptional mechanisms of liver X receptors alpha and beta, respectively. Biochem Biophys Res Commun. 2003; 310(2):589-593. PMID: 14521951
8. Hessvik NP, Boekschoten MV, Baltzersen MA, Kersten S, Xu X, Andersén H, et al. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux. Am J Physiol Endocrinol Metab. 2010; 298(3): E602-E613. doi: 10.1152/ajpendo.00553.2009 PMID: 19996385
9. Faulds MH, Zhao C, Dahlman-Wright K. Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases. Curr Opin Pharmacol. 2010; 10(6): 692-697. doi: 10.1016/j.coph.2010.07.003 PMID: 20829110
10. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000; 14(22): 2831-2838. PMID: 11090131
11. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003; 278(2): 1131-1136. PMID: 12414791
12. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A. 2003; 100(9): 5419-5424. PMID: 12697904
13. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, et al. Liver X receptor agonist TO901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology. 2006; 147(11): 5061-5068. PMID: 16873540
14. Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab. 2005; 289(5): E829-E838. PMID: 15941783
15. Lam TK, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab. 2003; 284(2): E281-E290. PMID: 12531742
16. Wilding JP. The importance of free fatty acids in the development of Type 2 diabetes. Diabet Med. 2007; 24(9): 934-945. PMID: 17725706
17. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011; 18(2): 139-143. doi: 10.1097/MED.0b013e3283444b09 PMID: 21297467
18. Matsuda M, Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract. 2013; 7(5): e330-e341. PMID: 24455761
19. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008; 57(8): 1071-1077. doi: 10.1016/j.metabol.2008.03.010 PMID: 18640384
20. Barazzoni R, Zanetti M, Gortan Cappellari G, Semolic A, Boschelle M, Codarin E, et al. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)-nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia. 2012; 55(3): 773-782. doi: 10.1007/s00125-011-2396-x PMID: 22159911
21. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006; 440(7086): 944-948. PMID: 16612386
22. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002; 420(6913): 333-336. PMID: 12447443
23. Jiang S, Messina JL. Role of inhibitory κB kinase and c-Jun NH2-terminal kinase in the development of hepatic insulin resistance in critical illness diabetes. Am J Physiol Gastrointest Liver Physiol. 2011; 301(3): G454-463. doi: 10.1152/ajpgi.00148.2011 PMID: 21680774
24. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem. 2004; 279: 45803-45809. PMID: 15331609
25. Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007; 116(2): 163-173. PMID: 17592079
26. Li X, Song Y, Han Y, Wang D, Zhu Y. Liver X receptor agonist alleviated high glucose-induced endothelial progenitor cell dysfunction via inhibition of reactive oxygen species and activation of AMP-activated protein kinase. Microcirculation. 2012; 19(6): 547-553. doi: 10.1111/j.1549-8719.2012.00186.x PMID: 22507035
27. Hassing HC, Mooij H, Guo S, Monia BP, Chen K, Kulik W, et al. Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. Hepatology. 2012; 55(6): 1746-1753. doi: 10.1002/hep.25580 PMID: 22234891
28. Liu S, Guo X, Wu B, Yu H, Zhang X, Li M. Arsenic induces diabetic effects through beta-cell dysfunction and increased gluconeogenesis in mice. Sci Rep. 2014; 4:6894. doi: 10.1038/srep06894 PMID: 25367288
29. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005; 7(7-8): 1040-1052.
30. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 1997; 43(7): 1209-1214. PMID: 9216458
31. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9(5): 367-377. doi: 10.1038/nrm2391 PMID: 18401346
32. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000; 14(22): 2819-2830. PMID: 11090130
33. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol. 2001; 21(9): 2991-3000. PMID: 11287605
34. Archer A, Laurencikiene J, Ahmed O, Steffensen KR, Parini P, Gustafsson JÅ, et al. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis. Am J Physiol Endocrinol Metab. 2014; 306(5): E494-E502. doi: 10.1152/ajpendo.00410.2013 PMID: 24368671
35. Grefhorst A, Hoekstra J, Derks TG, Ouwens DM, Baller JF, Havinga R, et al. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol. 2005; 289(3): G592-G598. PMID: 15817811
36. Muurling M, van den Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM, et al. Overexpression of APOC1 in ob/ob mice leads to hepatic steatosis and severe hepatic insulin resistance. J Lipid Res. 2004; 45(1): 9-16. PMID: 14523051
37. Gao M, Liu D. The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance. AAPS J. 2013; 15(1): 258-266. doi: 10.1208/s12248-012-9429-3 PMID: 23180161
38. Laplante M, Sabatini DM. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci U S A. 2010; 107(8): 3281-3282. doi: 10.1073/pnas.1000323107 PMID: 20167806
39. Stulnig TM, Steffensen KR, Gao H, Reimers M, Dahlman-Wright K, Schuster GU, et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol. 2002; 62(6): 1299-1305. PMID: 12435796
40. Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res. 2009; 48(1): 44-51. doi: 10.1016/j.plipres.2008.10.002 PMID: 19032965
41. Shi D, Zhan X, Yu X, Jia M, Zhang Y, Yao J, et al. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. Lipids Health Dis. 2014; 13(1): 173. doi: 10.1186/1476-511X-13-1 PMID: 24382338
42. Wang ZB, Zeng HC, Wei HS, Yi GH, Yu J, Wang YT, et al. NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signaling. J Pharm Pharmacol. 2012; 64(2): 293-301. doi: 10.1111/j.2042-7158.2011.01402.x PMID: 22221106
43. Le Lay S, Simard G, Martinez MC, Andriantsitohaina R. Oxidative Stress and Metabolic Pathologies: From an Adipocentric Point of View. Oxid Med Cell Longev 2014: 908539. doi: 10.1155/2014/908539 PMID: 25143800
44. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, Noda H, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem. 2009; 284(22): 14809-14818. doi: 10.1074/jbc.M901488200 PMID: 19332540
45. Pereira S, Park E, Mori Y, Haber CA, Han P, Uchida T, et al. FFA-induced Hepatic Insulin Resistance in vivo is mediated by PKC-ä, NADPH Oxidase, and Oxidative Stress. Am J Physiol Endocrinol Metab. 2014; 307: E34-E46. doi: 10.1152/ajpendo.00436.2013 PMID: 24824652
46. Díaz-Flores M, Cruz M, Duran-Reyes G, Munguia-Miranda C, Loza-Rodríguez H, Pulido-Casas E, et al. Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure. Can J Physiol Pharmacol. 2013; 91(10): 855-60. doi: 10.1139/cjpp-2012-0341 PMID: 24144057
47. Hokayem M, Blond E, Vidal H, Lambert K, Meugnier E, Feillet-Coudray C, et al. Grape polyphenols prevent fructose-induced oxidative stress and insulin resistance in first-degree relatives of type 2 diabetic patients. Diabetes Care. 2013; 36(6): 1454-1461. doi: 10.2337/dc12-1652 PMID: 23275372
48. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013; 1830(8): 4117-4129. doi: 10.1016/j.bbagen.2013.04.016 PMID: 23618697
49. Yamashita Y, Ueyama T, Nishi T, Yamamoto Y, Kawakoshi A, Sunami S, et al. Nrf2-inducing antioxidation stress response in the rat liver - new beneficial effect of lansoprazole. PLoS One. 2014; 9(5): e97419. doi: 10.1371/journal.pone.0097419 PMID: 24846271
50. Ramprasath T, Selvam GS. Potential impact of genetic variants in Nrf2 regulated antioxidant genes and risk prediction of diabetes and associated cardiac complications. Curr Med Chem. 2013; 20(37): 4680-4693. PMID: 23834171
51. Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia. 2011; 54(4): 922-934. doi: 10.1007/s00125-010-2001-8 PMID: 21161163
52. Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes. 2011; 60(2): 625-633. doi: 10.2337/db10-1164 PMID: 21270272
53. Gong H, He J, Lee JH, Mallick E, Gao X, Li S, et al. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J Biol Chem. 2009; 284(44): 30113-30121. doi: 10.1074/jbc.M109.047753 PMID: 19717840
54. He Q, Pu J, Yuan A, Lau WB, Gao E, Koch WJ, et al. Activation of Liver-X-Receptor α But Not Liver-X-Receptor β Protects Against Myocardial Ischemia/Reperfusion Injury. Circ Heart Fail. 2014; 7(6): 1032-1041. doi: 10.1161/CIRCHEARTFAILURE.114.001260 PMID: 25277999
55. He Q, Pu J, Yuan A, Yao T, Ying X, Zhao Y, et al. Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice. Cardiovasc Diabetol. 2014; 13(1): 149. PMID: 25416469